LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・Puma Biotechnology Inc

Puma Biotechnology Inc

Abierto

Sector Salud

2.5 -0.79

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.42

Máximo

2.55

Métricas clave
By Trading Economics
Ventas	16M 72M
BPA	0.26
Empleados	185

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 meses	+71.15 upside

Dividendos
By Dow Jones
Próximas Ganancias	31 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	13M 281M
Apertura anterior	3.29
Cierre anterior	2.5

Noticias sobre sentimiento de mercado

By Acuity

50%

97 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

2.25 / 2.58 Soporte y Resistencia

Puma Biotechnology Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 sept 2023, 20:47 UTC

Principales Movimientos del Mercado

Puma Biotechnology Stock Up 6.9% on New FDA Orphan Drug Designation

Comparación entre iguales

Cambio de precio

Puma Biotechnology Inc Esperado

Precio Objetivo

By TipRanks

71.15% repunte

Estimación a 12 meses

Media 4.33 USD 71.15%

Máximo 7 USD

Mínimo 2 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Puma Biotechnology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Puma Biotechnology Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

2.25 / 2.58Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

97 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Puma Biotechnology Inc

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to improve cancer care. The Company's products include PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357, as well as certain related compounds. Its lead product, NERLYNX, is an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI), that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment for patients with HER2-positive metastatic breast cancer. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors. The Company has two subsidiaries: Puma Biotechnology Ltd and Puma Biotechnology, B.V.